{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:20:35Z","timestamp":1789608035113,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"DOI":"10.7759\/cureus.85923","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:52:01Z","timestamp":1749822721000},"source":"Crossref","is-referenced-by-count":2,"title":["Effect of Biologic Therapies in Treating Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ooha","family":"Thadiboina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Saim Ali","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubela","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Hack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahpara","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qalandar","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amritveer","family":"Bhullar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Zargham Hussain","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Abdul Muhaimin","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Nureen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzat","family":"Izzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros B","year":"2023","unstructured":"Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023, 330:951-65. 10.1001\/jama.2023.15389","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du L","year":"2020","unstructured":"Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am. 2020, 49:643-54. 10.1016\/j.gtc.2020.07.005","journal-title":"Gastroenterol Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1840976","article-title":"Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia","volume":"15","author":"Wei SC","year":"2021","unstructured":"Wei SC, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJ, Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Rev Gastroenterol Hepatol. 2021, 15:275-89. 10.1080\/17474124.2021.1840976","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820931739","article-title":"Review of the epidemiology and burden of ulcerative colitis in Latin America","volume":"13","author":"Kotze PG","year":"2020","unstructured":"Kotze PG, Steinwurz F, Francisconi C, Zaltman C, Pinheiro M, Salese L, Ponce de Leon D. Review of the epidemiology and burden of ulcerative colitis in Latin America. Therap Adv Gastroenterol. 2020, 13:1756284820931739. 10.1177\/1756284820931739","journal-title":"Therap Adv Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/2050640615627533","article-title":"Risk factors for complications in patients with ulcerative colitis","volume":"4","author":"Manser CN","year":"2016","unstructured":"Manser CN, Borovicka J, Seibold F, Vavricka SR, Lakatos PL, Fried M, Rogler G. Risk factors for complications in patients with ulcerative colitis. United European Gastroenterol J. 2016, 4:281-7. 10.1177\/2050640615627533","journal-title":"United European Gastroenterol J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20897","article-title":"Risk factors and characteristics of extent progression in ulcerative colitis","volume":"15","author":"Etchevers MJ","year":"2009","unstructured":"Etchevers MJ, Aceituno M, Garc\u00eda-Bosch O, Ord\u00e1s I, Sans M, Ricart E, Pan\u00e9s J. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009, 15:1320-5. 10.1002\/ibd.20897","journal-title":"Inflamm Bowel Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.12.1526","article-title":"Risk factors for extensive ulcerative colitis and ulcerative proctitis: a population based case-control study","volume":"32","author":"Samuelsson SM","year":"1991","unstructured":"Samuelsson SM, Ekbom A, Zack M, Helmick CG, Adami HO. Risk factors for extensive ulcerative colitis and ulcerative proctitis: a population based case-control study. Gut. 1991, 32:1526-30. 10.1136\/gut.32.12.1526","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes","volume":"26","author":"Yu YR","year":"2017","unstructured":"Yu YR, Rodriguez JR. Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg. 2017, 26:349-55. 10.1053\/j.sempedsurg.2017.10.003","journal-title":"Semin Pediatr Surg"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S58153","article-title":"IBS-like symptoms in patients with ulcerative colitis","volume":"8","author":"Gracie DJ","year":"2015","unstructured":"Gracie DJ, Ford AC. IBS-like symptoms in patients with ulcerative colitis. Clin Exp Gastroenterol. 2015, 8:101-9. 10.2147\/CEG.S58153","journal-title":"Clin Exp Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i37.13234","article-title":"Biological therapy for ulcerative colitis: an update","volume":"20","author":"Seo GS","year":"2014","unstructured":"Seo GS, Chae SC. Biological therapy for ulcerative colitis: an update. World J Gastroenterol. 2014, 20:13234-8. 10.3748\/wjg.v20.i37.13234","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp140449","article-title":"Vedolizumab: an integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis","volume":"72","author":"Hahn L","year":"2015","unstructured":"Hahn L, Beggs A, Wahaib K, Kodali L, Kirkwood V. Vedolizumab: an integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis. Am J Health Syst Pharm. 2015, 72:1271-8. 10.2146\/ajhp140449","journal-title":"Am J Health Syst Pharm"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.03.003","article-title":"Interleukin 1\u03b2 blockade reduces intestinal inflammation in a murine model of tumor necrosis factor-independent ulcerative colitis","volume":"14","author":"Liso M","year":"2022","unstructured":"Liso M, Verna G, Cavalcanti E, et al.. Interleukin 1\u03b2 blockade reduces intestinal inflammation in a murine model of tumor necrosis factor-independent ulcerative colitis. Cell Mol Gastroenterol Hepatol. 2022, 14:151-71. 10.1016\/j.jcmgh.2022.03.003","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang DI","year":"2021","unstructured":"Jang DI, Lee AH, Shin HY, et al.. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021, 22:2719. 10.3390\/ijms22052719","journal-title":"Int J Mol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2021.03.002","article-title":"Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review","volume":"53","author":"Armuzzi A","year":"2021","unstructured":"Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: a narrative review. Dig Liver Dis. 2021, 53:803-8. 10.1016\/j.dld.2021.03.002","journal-title":"Dig Liver Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X16643242","article-title":"Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis","volume":"9","author":"Sofia MA","year":"2016","unstructured":"Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol. 2016, 9:548-59. 10.1177\/1756283X16643242","journal-title":"Therap Adv Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.242.bezz","article-title":"Overview of biological therapy in ulcerative colitis: current and future directions","volume":"24","author":"Furfaro F","year":"2015","unstructured":"Furfaro F, Bezzio C, Ardizzone S, Massari A, de Franchis R, Maconi G. Overview of biological therapy in ulcerative colitis: current and future directions. J Gastrointestin Liver Dis. 2015, 24:203-13. 10.15403\/jgld.2014.1121.242.bezz","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i20.6352","article-title":"Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis","volume":"21","author":"Jin Y","year":"2015","unstructured":"Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol. 2015, 21:6352-60. 10.3748\/wjg.v21.i20.6352","journal-title":"World J Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104455","article-title":"Infliximab clinically treating ulcerative colitis: a systematic review and meta-analysis","volume":"148","author":"Guo C","year":"2019","unstructured":"Guo C, Wu K, Liang X, Liang Y, Li R. Infliximab clinically treating ulcerative colitis: a systematic review and meta-analysis. Pharmacol Res. 2019, 148:104455. 10.1016\/j.phrs.2019.104455","journal-title":"Pharmacol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera C","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis. Inflamm Bowel Dis. 2022, 28:32-40. 10.1093\/ibd\/izab011","journal-title":"Inflamm Bowel Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.2210","article-title":"Effectiveness of adalimumab in severe ulcerative colitis: a systematic review and a meta-analysis","volume":"7","author":"Azadbakht S","year":"2024","unstructured":"Azadbakht S, Seighali M, Azadbakht S, Azadbakht M. Effectiveness of adalimumab in severe ulcerative colitis: a systematic review and a meta-analysis. Health Sci Rep. 2024, 7:e2210. 10.1002\/hsr2.2210","journal-title":"Health Sci Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher D","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, et al.. Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015, 4:1. 10.1186\/2046-4053-4-1","journal-title":"Syst Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000076","article-title":"Why the Cochrane risk of bias tool should not include funding source as a standard item","volume":"2013","author":"Sterne JA","year":"2013","unstructured":"Sterne JA. Why the Cochrane risk of bias tool should not include funding source as a standard item. Cochrane Database Syst Rev. 2013, 2013:ED000076. 10.1002\/14651858.ED000076","journal-title":"Cochrane Database Syst Rev"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo CK","year":"2014","unstructured":"Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014, 14:45. 10.1186\/1471-2288-14-45","journal-title":"BMC Med Res Methodol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-1070-0","article-title":"Introducing RAPTOR: RevMan parsing tool for reviewers","volume":"8","author":"Schmidt L","year":"2019","unstructured":"Schmidt L, Shokraneh F, Steinhausen K, Adams CE. Introducing RAPTOR: RevMan parsing tool for reviewers. Syst Rev. 2019, 8:151. 10.1186\/s13643-019-1070-0","journal-title":"Syst Rev"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap S","year":"2020","unstructured":"Honap S, Chee D, Chapman TP, et al.. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohns Colitis. 2020, 14:1385-93. 10.1093\/ecco-jcc\/jjaa075","journal-title":"J Crohns Colitis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh A","year":"2024","unstructured":"Singh A, Goyal MK, Midha V, et al.. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024, 119:1365-72. 10.14309\/ajg.0000000000002635","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.031","article-title":"OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial","volume":"11","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Sands BE, Danese S, et al.. OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial. J Crohns Colitis. 2017, 11:19-20. 10.1093\/ecco-jcc\/jjx002.031","journal-title":"J Crohns Colitis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-015-0239-9","article-title":"Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes","volume":"15","author":"Pan\u00e9s J","year":"2015","unstructured":"Pan\u00e9s J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol. 2015, 15:14. 10.1186\/s12876-015-0239-9","journal-title":"BMC Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2358183","article-title":"Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study","volume":"56","author":"Ollech JE","year":"2024","unstructured":"Ollech JE, Eran-Banai H, Goren I, et al.. Tofacitinib is an effective treatment for moderate to severe ulcerative colitis, and intestinal ultrasound can discriminate response from non-response: a pragmatic prospective real-world study. Ann Med. 2024, 56:2358183. 10.1080\/07853890.2024.2358183","journal-title":"Ann Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.17235\/reed.2022.8380\/2021","article-title":"Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia","volume":"114","author":"Hern\u00e1ndez Mart\u00ednez A","year":"2022","unstructured":"Hern\u00e1ndez Mart\u00ednez A, Navajas Hern\u00e1ndez P, Mart\u00edn Rodr\u00edguez MD, et al.. Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia. Rev Esp Enferm Dig. 2022, 114:516-21. 10.17235\/reed.2022.8380\/2021","journal-title":"Rev Esp Enferm Dig"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD research consortium multicenter national cohort study","volume":"118","author":"Ma C","year":"2023","unstructured":"Ma C, Panaccione R, Xiao Y, et al.. REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD research consortium multicenter national cohort study. Am J Gastroenterol. 2023, 118:861-71. 10.14309\/ajg.0000000000002129","journal-title":"Am J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.34172\/aim.2021.52","article-title":"Efficacy and safety of tofacitinib for treatment of moderate to severe active ulcerative colitis: first report from Iran","volume":"24","author":"Jameshorani M","year":"2021","unstructured":"Jameshorani M, Vahedi H, Sadeghi A, et al.. Efficacy and safety of tofacitinib for treatment of moderate to severe active ulcerative colitis: first report from Iran. Arch Iran Med. 2021, 24:354-63. 10.34172\/aim.2021.52","journal-title":"Arch Iran Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.579","article-title":"P452 tofacitinib effectiveness and safety as therapy for ulcerative colitis","volume":"16","author":"McNally M","year":"2022","unstructured":"McNally M, Keating E, Gray E, et al.. P452 tofacitinib effectiveness and safety as therapy for ulcerative colitis. J Crohns Colitis. 2022, 16:431. 10.1093\/ecco-jcc\/jjab232.579","journal-title":"J Crohns Colitis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, Niezychowski W. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012, 367:616-24. 10.1056\/NEJMoa1112168","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/zaa010.185","article-title":"P087 Real-world effectiveness of ustekinumab in ulcerative colitis","volume":"26","author":"Hong S","year":"2020","unstructured":"Hong S, Zullow S, Axelrad J, Chang S, Hudesman D. P087 Real-world effectiveness of ustekinumab in ulcerative colitis. Inflamm Bowel Dis. 2020, 26:73-4. 10.1093\/ibd\/zaa010.185","journal-title":"Inflamm Bowel Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2022-102168","article-title":"Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study","volume":"13","author":"Honap S","year":"2022","unstructured":"Honap S, Al-Hillawi L, Baillie S, et al.. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. 2022, 13:517-23. 10.1136\/flgastro-2022-102168","journal-title":"Frontline Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-08977-1","article-title":"Long-term effectiveness and safety of ustekinumab dose escalation in patients with moderate-to-severe ulcerative colitis: a multicenter retrospective cohort study","author":"van Lierop LM","year":"2025","unstructured":"van Lierop LM, Albino L, Rosentreter R, et al.. Long-term effectiveness and safety of ustekinumab dose escalation in patients with moderate-to-severe ulcerative colitis: a multicenter retrospective cohort study. Dig Dis Sci. 2025, 10.1007\/s10620-025-08977-1","journal-title":"Dig Dis Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab002","article-title":"Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States","volume":"3","author":"Hong SJ","year":"2021","unstructured":"Hong SJ, Krugliak Cleveland N, Akiyama S, et al.. Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States. Crohns Colitis 360. 2021, 3:otab002. 10.1093\/crocol\/otab002","journal-title":"Crohns Colitis 360"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1981855","article-title":"One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy","volume":"21","author":"Chiappetta MF","year":"2021","unstructured":"Chiappetta MF, Viola A, Mastronardi M, et al.. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021, 21:1483-9. 10.1080\/14712598.2021.1981855","journal-title":"Expert Opin Biol Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18272","article-title":"Editorial: effectiveness and safety of ustekinumab in ulcerative colitis-where we are now in real life","volume":"60","author":"Mocci G","year":"2024","unstructured":"Mocci G, Tursi A. Editorial: effectiveness and safety of ustekinumab in ulcerative colitis-where we are now in real life. Aliment Pharmacol Ther. 2024, 60:1459-60. 10.1111\/apt.18272","journal-title":"Aliment Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.088","article-title":"DOP54 efficacy and safety of ustekinumab through week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial","volume":"13","author":"Danese S","year":"2019","unstructured":"Danese S, Sands B, O'Brien C, et al.. DOP54 efficacy and safety of ustekinumab through week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. J Crohns Colitis. 2019, 13:061-2. 10.1093\/ecco-jcc\/jjy222.088","journal-title":"J Crohns Colitis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otae023","article-title":"Effectiveness and safety of ustekinumab for ulcerative colitis: a Brazilian multicentric observational study","volume":"6","author":"Parra RS","year":"2024","unstructured":"Parra RS, Chebli JM, de Azevedo MF, et al.. Effectiveness and safety of ustekinumab for ulcerative colitis: a Brazilian multicentric observational study. Crohns Colitis 360. 2024, 6:otae023. 10.1093\/crocol\/otae023","journal-title":"Crohns Colitis 360"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15717","article-title":"Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study","volume":"51","author":"Amiot A","year":"2020","unstructured":"Amiot A, Filippi J, Abitbol V, et al.. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020, 51:1039-46. 10.1111\/apt.15717","journal-title":"Aliment Pharmacol Ther"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae058","article-title":"Real-world effectiveness of ustekinumab in ulcerative colitis in a United States multicenter cohort consortium","volume":"31","author":"Yarur AJ","year":"2025","unstructured":"Yarur AJ, Ungaro R, Huang K, et al.. Real-world effectiveness of ustekinumab in ulcerative colitis in a United States multicenter cohort consortium. Inflamm Bowel Dis. 2025, 31:131-9. 10.1093\/ibd\/izae058","journal-title":"Inflamm Bowel Dis"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0162-0","article-title":"Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium","volume":"113","author":"Narula N","year":"2018","unstructured":"Narula N, Peerani F, Meserve J, et al.. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium. Am J Gastroenterol. 2018, 113:1345. 10.1038\/s41395-018-0162-0","journal-title":"Am J Gastroenterol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S, et al.. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020, 158:562-572.e12. 10.1053\/j.gastro.2019.08.027","journal-title":"Gastroenterology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya S","year":"2019","unstructured":"Motoya S, Watanabe K, Ogata H, et al.. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019, 14:e0212989. 10.1371\/journal.pone.0212989","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw177","article-title":"Long-term efficacy of vedolizumab for ulcerative colitis","volume":"11","author":"Loftus EV Jr","year":"2017","unstructured":"Loftus EV Jr, Colombel JF, Feagan BG, et al.. Long-term efficacy of vedolizumab for ulcerative colitis. J Crohns Colitis. 2017, 11:400-11. 10.1093\/ecco-jcc\/jjw177","journal-title":"J Crohns Colitis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002229","article-title":"Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study","volume":"33","author":"Attauabi M","year":"2021","unstructured":"Attauabi M, Vind I, Pedersen G, Bendtsen F, Seidelin JB, Burisch J. Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease - a real-world two-center cohort study. Eur J Gastroenterol Hepatol. 2021, 33:e709-18. 10.1097\/MEG.0000000000002229","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan BG","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, et al.. Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017, 15:229-239.e5. 10.1016\/j.cgh.2016.08.044","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i47.10432","article-title":"Short-term effectiveness of golimumab for ulcerative colitis: observational multicenter study","volume":"22","author":"Bosca-Watts MM","year":"2016","unstructured":"Bosca-Watts MM, Cortes X, Iborra M, et al.. Short-term effectiveness of golimumab for ulcerative colitis: observational multicenter study. World J Gastroenterol. 2016, 22:10432-9. 10.3748\/wjg.v22.i47.10432","journal-title":"World J Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2021.1963466","article-title":"Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG","volume":"56","author":"Eriksson C","year":"2021","unstructured":"Eriksson C, Visuri I, Vigren L, et al.. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol. 2021, 56:1304-11. 10.1080\/00365521.2021.1963466","journal-title":"Scand J Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05904-z","article-title":"Real-life effectiveness and safety of golimumab and its predictors of response in patients with ulcerative colitis","volume":"65","author":"Bossa F","year":"2020","unstructured":"Bossa F, Biscaglia G, Valvano MR, et al.. Real-life effectiveness and safety of golimumab and its predictors of response in patients with ulcerative colitis. Dig Dis Sci. 2020, 65:1767-76. 10.1007\/s10620-019-05904-z","journal-title":"Dig Dis Sci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.15403\/jgld.2014.1121.263.trs","article-title":"Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers","volume":"26","author":"Tursi A","year":"2017","unstructured":"Tursi A, Allegretta L, Buccianti N, et al.. Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases centers. J Gastrointestin Liver Dis. 2017, 26:239-44. 10.15403\/jgld.2014.1121.263.trs","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001177","article-title":"Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis","volume":"30","author":"O\u2019Connell J","year":"2018","unstructured":"O\u2019Connell J, Rowan C, Stack R, et al.. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology & Hepatology. 2018, 30:1019-1026. 10.1097\/MEG.0000000000001177","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221074188","article-title":"Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland","volume":"15","author":"Perrig K","year":"2022","unstructured":"Perrig K, Krupka N, Jordi SB, et al.. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol. 2022, 15:17562848221074188. 10.1177\/17562848221074188","journal-title":"Therap Adv Gastroenterol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwy019","article-title":"Real world effectiveness of golimumab therapy in ulcerative colitis regardless of prior TNF exposure","volume":"1","author":"Bressler B","year":"2018","unstructured":"Bressler B, Williamson M, Sattin B, Camacho F, Steinhart AH. Real world effectiveness of golimumab therapy in ulcerative colitis regardless of prior TNF exposure. J Can Assoc Gastroenterol. 2018, 1:129-34. 10.1093\/jcag\/gwy019","journal-title":"J Can Assoc Gastroenterol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17421","article-title":"Effectiveness of golimumab intensification in ulcerative colitis: a multicentric prospective study","volume":"57","author":"Fumery M","year":"2023","unstructured":"Fumery M, Nancey S, Filippi J, et al.. Effectiveness of golimumab intensification in ulcerative colitis: a multicentric prospective study. Aliment Pharmacol Ther. 2023, 57:1290-8. 10.1111\/apt.17421","journal-title":"Aliment Pharmacol Ther"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00033","article-title":"Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study","volume":"19","author":"Ogata H","year":"2021","unstructured":"Ogata H, Hagiwara T, Kawaberi T, Kobayashi M, Hibi T. Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study. Intest Res. 2021, 19:419-29. 10.5217\/ir.2020.00033","journal-title":"Intest Res"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.10.004","article-title":"Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome","volume":"7","author":"Garc\u00eda-Bosch O","year":"2013","unstructured":"Garc\u00eda-Bosch O, Gisbert JP, Ca\u00f1as-Ventura A, et al.. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013, 7:717-22. 10.1016\/j.crohns.2012.10.004","journal-title":"J Crohns Colitis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1713210","article-title":"Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study","volume":"55","author":"Angelison L","year":"2020","unstructured":"Angelison L, Almer S, Davidsdottir L, et al.. Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study. Scand J Gastroenterol. 2020, 55:154-62. 10.1080\/00365521.2020.1713210","journal-title":"Scand J Gastroenterol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki Y","year":"2014","unstructured":"Suzuki Y, Motoya S, Hanai H, et al.. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014, 49:283-94. 10.1007\/s00535-013-0922-y","journal-title":"J Gastroenterol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.03.018","article-title":"Adalimumab in active ulcerative colitis: a \"real-life\" observational study","volume":"45","author":"Armuzzi A","year":"2013","unstructured":"Armuzzi A, Biancone L, Daperno M, et al.. Adalimumab in active ulcerative colitis: a \"real-life\" observational study. Dig Liver Dis. 2013, 45:738-43. 10.1016\/j.dld.2013.03.018","journal-title":"Dig Liver Dis"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al.. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012, 142:257-65.e1-3. 10.1053\/j.gastro.2011.10.032","journal-title":"Gastroenterology"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.4103\/jcmrp.jcmrp_31_16","article-title":"Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis","volume":"2","author":"Mohamed KF","year":"2017","unstructured":"Mohamed KF, Ismail AA, Hassan EA, Ramadan HK, El-Attar MM. Efficacy and safety of infliximab on colonic mucosal healing in patients with moderate-to-severe ulcerative colitis. J Curr Med Res Pract. 2017, 2:42-6. 10.4103\/jcmrp.jcmrp_31_16","journal-title":"J Curr Med Res Pract"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.23736\/S1121-421X.17.02402-3","article-title":"Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real\u2011life experience in IBD primary centers","volume":"63","author":"Tursi A","year":"2017","unstructured":"Tursi A, Allegretta L, Chiri S, et al.. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real\u2011life experience in IBD primary centers. Minerva Gastroenterol Dietol. 2017, 63:313-8. 10.23736\/S1121-421X.17.02402-3","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa JS","year":"2022","unstructured":"Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022, 7:161-70. 10.1016\/S2468-1253(21)00377-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326390","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","author":"Burr NE","year":"2021","unstructured":"Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021, 10.1136\/gutjnl-2021-326390","journal-title":"Gut"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese S","year":"2014","unstructured":"Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014, 160:704-11. 10.7326\/M13-2403","journal-title":"Ann Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371945-effect-of-biologic-therapies-in-treating-moderate-to-severe-ulcerative-colitis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T13:52:02Z","timestamp":1749822722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371945-effect-of-biologic-therapies-in-treating-moderate-to-severe-ulcerative-colitis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":70,"URL":"https:\/\/doi.org\/10.7759\/cureus.85923","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}